Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
Julphar
Queensland Health
Moodys
Johnson and Johnson
AstraZeneca
Chinese Patent Office
Baxter

Generated: June 25, 2018

DrugPatentWatch Database Preview

DESVENLAFAXINE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Desvenlafaxine patents expire, and when can generic versions of Desvenlafaxine launch?

Desvenlafaxine is a drug marketed by Alembic Pharms Ltd, Sun Pharma Global, Teva Pharms Usa, Actavis Labs Fl, Casi Pharms Inc, Lupin Ltd, Mylan Pharms Inc, West-ward Pharms Int, and Zydus Pharms Usa Inc. and is included in eleven NDAs.

The generic ingredient in DESVENLAFAXINE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Drug patent expirations by year for DESVENLAFAXINE
Medical Subject Heading (MeSH) Categories for DESVENLAFAXINE
Synonyms for DESVENLAFAXINE
130198-08-2
93414-04-1
CHEMBL3039565
Desvenlafaxine fumarate
O-Desmethylvenlafaxine fumarate
Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-, (2E)-2-butenedioate (1:1) (salt)
Phenol, 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)-, (E)-2-butenedioate (1:1) (salt)
SCHEMBL3400998
SCHEMBL521350
SQTJDJZCPOSWSC-WLHGVMLRSA-N

US Patents and Regulatory Information for DESVENLAFAXINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic Pharms Ltd DESVENLAFAXINE desvenlafaxine TABLET, EXTENDED RELEASE;ORAL 204150-001 Mar 4, 2013 BC RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082-002 Aug 28, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sun Pharma Global DESVENLAFAXINE desvenlafaxine fumarate TABLET, EXTENDED RELEASE;ORAL 205583-002 Jan 28, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Medtronic
Covington
Johnson and Johnson
Chubb
Cipla
Harvard Business School
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.